Year: 2020
BERGENBIO TO PRESENT AT Sachs Annual Biotech in Europe Forum
September 18, 2020
Bergen, Norway, 18 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO TO PRESENT AT UPCOMING INVESTOR CONFERENCES
September 1, 2020
Bergen, Norway, 01 September 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO ASA: RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2020
August 18, 2020
Bergen, Norway, 18 August 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation
August 10, 2020
Bergen, Norway, 10 August 2020 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreUPDATE ON BEMCENTINIB’S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC
July 28, 2020
BerGenBio in late stage set-up phase to sponsor and conduct a clinical study using bemcentinib…
Read MoreBERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I/II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINIB
July 20, 2020
Bergen, Norway, 20 July 2020 –BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More
